Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 195   

Articles published

AZN 3,781.50 +23.00 (0.61%)
price chart
AstraZeneca Plc's Greatest Strengths
When I think of pharmaceutical company AstraZeneca (LSE: AZN) (NYSE: AZN.US), two factors jump out at me as the firm's greatest strengths and top the list of what makes the company attractive as an investment proposition.
AstraZeneca plc: The 'Sell' That Has Been A Great 'Buy'
In recent years, I seem to have read nothing but bad news about pharmaceutical giant AstraZeneca (LSE: AZN) (NYSE: AZN.US).
Related articles »  
AstraZeneca Plc After The Patent Cliff
The thing about technological and scientific change is that it can happen very quickly. University start-ups can be transformed into global titans - think of Facebook.
What AstraZeneca plc's Investment Plans Mean For Earnings Growth
As one would expect, AstraZeneca is required to chuck vast sums of money into R&D in order to stay at the cutting edge of healthcare technology and develop the next generation of super-drugs.
Zacks Reiterates "Neutral" Rating for AstraZeneca plc (AZN)
Zacks reissued their neutral rating on shares of AstraZeneca plc (NYSE:AZN) in a research note released on Friday morning, AmericanBankingNews.
Related articles »  
AstraZeneca plc Given "Underweight" Rating at JPMorgan Chase & Co. (AZN)
JPMorgan Chase & Co. reiterated their underweight rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Thursday morning, AnalystRatings.
AstraZeneca plc Stock Rating Reaffirmed by Jefferies Group (AZN)  Ticker Report
Related articles »  
Better Buy: Eli Lilly & Co. or AstraZeneca plc?
Among the leaders are Eli Lilly (NYSE: LLY ) and AstraZeneca (NYSE: AZN ) . Both offer short and long-term insulin therapies generating billions in annual revenue, but both are also facing short-term headwinds tied to high-profile patent expirations.
Related articles »  
AstraZeneca plc Rating Increased to Hold at Panmure Gordon (AZN)
AstraZeneca plc logo AstraZeneca plc (LON:AZN) was upgraded by stock analysts at Panmure Gordon to a �hold� rating in a report issued on Tuesday, American Banking News reports.
AstraZeneca plc Given Hold Rating at Deutsche Bank (AZN)  Ticker Report
AstraZeneca plc Given Underperform Rating at Credit Suisse (AZN)  Mideast Time
Related articles »  
Citigroup Inc. Reiterates Neutral Rating for AstraZeneca plc (AZN)
AstraZeneca plc logo Citigroup Inc. reaffirmed their neutral rating on shares of AstraZeneca plc (LON:AZN) in a report released on Thursday, American Banking & Market News reports.
Related articles »  
AstraZeneca plc Rating Reiterated by Beaufort Securities (AZN)
AstraZeneca plc (LON:AZN) opened at 3883.50 on Monday. AstraZeneca plc has a 52 week low of GBX 3028.50 and a 52 week high of GBX 4115.00.
Beaufort Securities Reiterates Sell Rating for AstraZeneca plc (AZN)  Ticker Report
AstraZeneca plc Stock Rating Reaffirmed by Beaufort Securities (AZN)  Mideast Time
Related articles »